Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Executive Summary

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.


Related Content

IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public
Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta
Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m
Takeda Catches Rising Tide Of Antisense Neuroscience R&D
Celgene diversifies with $7.2bn Receptos buy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts